Previous Close | 39.83 |
Open | 39.71 |
Bid | 39.96 x N/A |
Ask | 40.02 x N/A |
Day's Range | 39.88 - 40.26 |
52 Week Range | 36.63 - 41.36 |
Volume | |
Avg. Volume | 1,970 |
Market Cap | 8.874B |
Beta (5Y Monthly) | 0.42 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
Forward Dividend & Yield | 1.18 (2.83%) |
Ex-Dividend Date | Jan 30, 2024 |
1y Target Est | N/A |
Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification // DNA quantification enables law enforcement and forensic researchers to analyze a broader range of evidence more quickly, accurately and reliably // Collaboration strengthens QIAGEN’s leading position in human identification and forensicsVenlo, the Netherlands, and Washington, D.C., May 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGE
Review Qiagen's (QGEN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances precision medicine by enabling smaller and decentralized labs to adopt NGS testing with efficiency, consistency and confidence // Combination of QCI Secondary Analysis and QCI Interpret provide a secure and compliant environment for trusted and scalable bioinformatics workflows for oncology and inher